 The mainstay of therapy for GISTs is surgical resection, however, recurrence is almost inevitable in high-risk tumors and secondary surgery or other salvage therapy has yielded poor outcome. The median survival for patients with unresectable or metastatic GIST is approximately 20 months, and for patients with local recurrence it is 9 to 12 months. Responses to chemotherapy have been at best 5. The introduction of imatinib has dramatically changed the prognosis of these patients yielding response rates between 41 and 71 and an overall clinical benefit tumor responses plus stable disease ranging between 73 and 90. 